Idacio

Indicated For

rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis

About This Medication

# KabiCare Patient Support Program Patient Guide: How to Get Idacio (adalimumab-aacf) at Low or No Cost Idacio (adalimumab-aacf) is an FDA-approved biosimilar to Humira (adalimumab), offered through Fresenius Kabi's **KabiCare Patient Support Program**. This guide explains how eligible patients can access **Idacio** at low or no cost via copay assistance, patient assistance, or reimbursement options.[3][5] ## About Idacio (adalimumab-aacf) **Idacio** is a biosimilar medication used to treat conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. As a biosimilar to Humira, it has the same active ingredient, adalimumab-aacf, but may offer more affordable access. It's given by injection, often as 2 x 40 mg doses in one day or other specified dosing.[2][3] Always follow your doctor's instructions for use, storage, and administration. KabiCare provides nurse support for education on injection training and disease management.[5][7] ## Who Qualifies for KabiCare? The **KabiCare Patient Support Program** supports patients through copay assistance for commercially insured individuals, patient assistance for uninsured or underinsured, bridge-to-therapy, and reimbursement. **Eligibility criteria apply**—specific income thresholds are not detailed publicly, but general criteria include residency in the US and not being enrolled in federal or state programs that reimburse prescriptions.[1][5] Your healthcare provider (HCP) can help determine eligibility. Commercially insured patients may reduce out-of-pocket costs to **$0/month** up to an annual maximum. Uninsured patients may qualify for free medication via the Patient Assistance Program.[5] ## Income Eligibility Breakdown Detailed income limits (e.g., Federal Poverty Level percentages) are **not specified** in program sources. Eligibility is based on financial need, insurance status, and other criteria. Contact KabiCare at **(833) 522-4227** for a personalized assessment.[1] | Household Size | Income Threshold | Notes | |---------------|------------------|-------| | Individual | Not specified | Eligibility criteria apply; call for details | | Couple | Not specified | May include Patient Assistance Program for uninsured | | Family of 3 | Not specified | Financial assistance available if cannot afford medication | | Family of 4 | Not specified | Annual maximum benefits for copay | **Note**: Income verification may be required for Patient Assistance Program enrollment.[5][6] ## Insurance Requirements - **Commercially insured**: Eligible for **copay assistance** to lower costs to $0/month (annual max applies). **Not eligible** if prescription is reimbursed by state/federal programs like Medicare, Medicaid, VA, Tricare, or similar.[1][5] - **Uninsured/underinsured**: May qualify for **Patient Assistance Program** for free or low-cost Idacio.[5] - **Bridge to Therapy**: Free medication while awaiting insurance approval (commercial insurance only).[5][6] KabiCare offers **Benefits Investigation**, prior authorization support, and appeals assistance.[6] ## Step-by-Step Application Process KabiCare offers **multiple enrollment methods** for flexibility. Involve your HCP for best results.[1][3] 1. **Discuss with your HCP**: Confirm Idacio prescription and ask them to enroll you online or complete the enrollment form.[3] 2. **Choose enrollment option**: - **Full KabiCare Program**: Download form from [kabicare.us](https://www.kabicare.us/patient/program/adalimumab-aacf/how-to-enroll/), have HCP sign, and fax to number on form (e.g., 1-888-304-2014).[1][2] - **Copay Only (Online)**: Visit enrollment link or call **(833) 522-4227**.[1] - **Phone Enrollment**: Call **1-833-KABICARE (833-522-4227)** for copay support.[1] 3. **Provide required info**: Patient details, insurance info, HCP signature, and consent for data use.[2] 4. **For Reimbursement** (if already paid out-of-pocket): - Enroll first. - Submit **itemized receipt with NDC details and drug name** to: KabiCare Copay Program, 2250 Perimeter Park Dr., Suite 300, Morrisville, NC 27560 (Fax: 833-671-1010). - 180-day lookback from enrollment.[1] 5. **Sign and submit**: Ensure signature to avoid delays.[1] Once enrolled, expect a **welcome packet** by mail with medication info and program details. A case manager will call to review benefits.[5] ## Timeline and Delivery - **Processing**: Reimbursement checks arrive in **7-14 business days**. General enrollment processing varies but aims for quick access.[1] - **Delivery**: Medication **shipped directly to patient** or pharmacy via Bridge program. Refill reminders and nurse support included.[5][7] - Full enrollment includes copay activation automatically.[1] ## Alternatives if Denied or Ineligible - **Appeal**: KabiCare provides **claims appeals support** with sample letters.[6] - **Independent nonprofits**: Explore RxAssist.org or other PAPs for Idacio alternatives.[9] - **Biosimilar options**: No specific alternatives listed; discuss with HCP.[ ] - **Bridge to Therapy**: If commercially insured and waiting for approval.[5] Contact KabiCare for financial assistance enrollment into other programs.[5] ## Additional KabiCare Support - **Nurse Educators**: Help with disease education, injection training (not a substitute for HCP advice).[5][6] - **Case Management**: Insurance navigation, prior auth forms prepopulated.[6] ## Disclaimer This guide is for informational purposes based on publicly available KabiCare details as of latest sources. **Eligibility, benefits, and terms can change**—always verify with KabiCare at (833) 522-4227 or kabicare.us. Not a guarantee of coverage. Consult your healthcare provider before starting Idacio. KabiCare does not replace medical advice. Program administered by Fresenius Kabi; eligibility criteria strictly apply.[1][5]

Program information last verified: March 30, 2026